Skip to main content
Signal8

INTERPACE BIOSCIENCES, INC. (IDXG) Form 8-K — Nov 17, 2026

$IDXGForm 8-KItems 2.02, 9.01Filed Nov 17, 2026, 4:15 PM ET0001493152-26-052840Original filing

Interpace Biosciences reported Q3 2026 revenue of $10.4 million, up 18% year-over-year, with thyroid volume up 7% and thyroid revenue up 18%. Gross margin expanded to 69% from 62%, and Adjusted EBITDA rose to $2.1 million (20% margin) from $1.3 million (14%). However, the company swung to a $1.5 million GAAP loss from continuing operations versus $1.0 million income a year ago, driven by approximately $4.1 million of non-recurring stock compensation and legal expenses. The company remains debt-free with $2.9 million in cash.

Key figures

Revenue
10373000
Total Debt
0
Revenue Yoy
18%
Total Assets
37468000
Cash Position
2929000
Q3 2025 revenue
8756000
Ttm thyroid revenue
38000000
Gross margin q3 2025
62%
Gross margin q3 2026
69%
Operating loss q3 2026
2400000
Adjusted ebitda q3 2025
1263000
Adjusted ebitda q3 2026
2072000
Nine month revenue 2025
29504000
Nine month revenue 2026
28537000
Cash collections q3 2026
9100000
Non recurring charges q3
4100000
Thyroid volume growth yoy
7%
Thyroid revenue growth yoy
18%
Adjusted ebitda margin q3 2025
14%
Adjusted ebitda margin q3 2026
20%
Nine month revenue 2025 pro forma
25311000
Avg thyroid revenue per test growth
11%

AI analysis

Red flags4 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    INTERPACE BIOSCIENCES, INC. (IDXG) Form 8-K — Nov 17, 2026: AI Analysis | Signal8